ddrmachineforsale| Laikai Pharmaceuticals-B is now up by more than 8% and its Phase III clinical trial plan for combination therapy for prostate cancer has been approved by the US FDA

Laikai Pharmaceuticals-B (02105) rose 8 against the marketddrmachineforsale.29%, currently reported at 7ddrmachineforsale.71 Hong Kong dollars, with a turnover of 40.6963 million Hong Kong dollars.

Laikai Pharmaceuticals announced that the group has obtained a consultation from the U.S. Food and Drug Administration on LAE002 (afuresertib, an AKT inhibitor) combined with LAE001 (CYP17A1/CYP11B2 dual inhibitor) for treatment after standard treatment.ddrmachineforsalePhase III clinical trial protocol in patients with metastatic castration-resistant prostate cancer (mCRPC)ddrmachineforsaleapproval.